Found 81 clinical trials
Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)
This study evaluates the addition of Acalabrutinib to current standard therapy of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) for patients with previously
- 0 views
- 04 Nov, 2021
- 3 locations
Imaging Apoptosis for Lymphoma Treatment Response
therapies such as rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) used to treat diffuse large B-cell lymphoma (DLBCL). Caspase-3 activation occurs as a result of apoptosis
- 0 views
- 18 Dec, 2021
- 1 location
Effect of Dapagliflozin vs Sitagliptin on Liver Fat Accumulation and Body Composition in Patients With Diabetes Mellitus and Liver Transplantation (Dapa-LiT)
transplantation. As these patients receive oral glucocorticoids (mostly prednisolone) and immunosuppressants, which elevate blood glucose levels, multiple doses of insulin are usually required. After 2-3 months
- 0 views
- 24 Mar, 2022
- 1 location
Phase 4 Study of Mepolizumab 100 Milligram (mg) Subcutaneous (SC) in Indian Subjects Aged >=18 Years With Severe Eosinophilic Asthma Requiring Maintenance Oral Corticosteroids
adjust the OCS (prednisone/prednisolone) dose according to the Optimization titration schedule based on a review of Asthma Control Questionnaire (ACQ)-5 score and exacerbation. During the Reduction
- 0 views
- 15 Jun, 2022
- 10 locations
Treatment Effects of Chinese Medicine (Yi-Qi-Qing-Jie Herbal Compound) Combined With Immunosuppression Therapies in IgA Nephropathy Patients With High-risk of ESRD (TCMWINE)
The TCM-WINE study is a single-center, prospective, double-blind randomized placebo-controlled trial. Based on optimal supportive care, the trial is aiming to assess superiority with regard to renal protection and reduction of severe treatment-related adverse events of Yi-Qi-Qing-Jie formula (YQF) combined therapy compared with immunosuppression monotherapy in high-risk IgAN.
- 20 views
- 27 Feb, 2022
- 1 location
RCT Comparing Immunosuppressive Regimens in Elderly Renal Transplant Recipients (OPTIMIZE)
Open label, randomized, multicenter, intervention trial comparing standard immunosuppression with tacrolimus and mycophenolate mofetil with a low exposure tacrolimus regimen in combination with everolimus. The primary objective is to test the hypothesis that an age-adapted immunosuppressive regimen targeted at reduced immunosuppression with low calcineurin inhibitor (tacrolimus) exposure in combination with …
- 5 views
- 16 May, 2022
- 7 locations
Minimizing Glucocorticoid Administration in Patients With Proliferative Lupus Nephritis (GLUREDLUP)
The aim of the study is to evaluate the efficacy of a therapeutic regimen which decreases glucocorticoid exposure compared with standard therapy in patients with proliferative lupus nephritis during remission induction by evaluating the histological and clinical remission.
- 0 views
- 11 Mar, 2022
- 1 location
Effectiveness of COVID-19 Vaccine in Hematopoietic Stem Cell Transplant Patients (ESCVHSCT)
COVID-19 vaccinations are predicted to be a huge success in pandemic control. However, the majority of the studies were conducted on healthy individuals, and the efficiency of COVID-19 vaccination in post-transplant patients is uncertain. In the setting of HSCT, the extreme immunosuppression caused by the conditioning regimen and the graft …
- 0 views
- 28 May, 2022
- 1 location
Once Weekly Infant Corticosteroid Trial for DMD
The hypothesis tested here is that a lower dose of intermittent oral corticosteroids (5mg/kg/week) will be equally effective to the 10mg/kg/week dose.
- 0 views
- 13 Jun, 2022
- 1 location
A Phase IIIb, Open-label, Single-arm, Single-dose, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of Gene Replacement Therapy With Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA) (SMART)
To evaluate the safety, tolerability and efficacy of intravenous administration of OAV101 (AVXS-101) in patients with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene weighing ≥ 8.5 kg and ≤ 21 kg, over a 12 month period.
- 4 views
- 22 Oct, 2022
- 2 locations